Jean-Claude Provost - 02 Mar 2023 Form 4 Insider Report for Lantheus Holdings, Inc. (LNTH)

Role: Chief Medical Officer
Signature: /s/ Eric Green, attorney-in-fact
Issuer symbol: LNTH
Transactions as of: 02 Mar 2023
Net transactions value: $0
Form type: 4
Filing time: 06 Mar 2023, 20:11:00 UTC
Previous filing: 10 Jan 2023
Next filing: 05 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LNTH	Common Stock	Award	$0	+16,359	+366%	$0.000000	20,823	02 Mar 2023	By Theranostics Consulting SAS	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LNTH	Stock Option (right to buy)	Award	$0	+9,535		$0.000000	9,535	02 Mar 2023	Common Stock	9,535	$73.35	By Theranostics Consulting SAS	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of 5,453 restricted stock units that vest in equal installments over a three-year period and 10,906 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award, however the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period.
F2	The reporting person is the managing partner of the company that owns the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F3	The option vests in three equal annual installments beginning on March 2, 2024.